Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human ADME · 1 trial · 1 indication
To describe the single dose pharmacokinetics (Cmax, Tmax, AUC, t 1/2, CL/F) of total radioactivity in plasma, whole blood, urine and feces following oral (PO) administration of \[14C\] TR 701 in healthy adult male subjects
| Arm | Type | Description |
|---|---|---|
| Human ADME | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Human ADME | DRUG | Oral single dose |
Inclusion Criteria: 1. Males, between 18 and 50 years of age, inclusive. 2. Body mass index (BMI) of 20 kg/m2 to 29.9 kg/m2, inclusive. 3. In good health, determined by no clinically significant findings from medical history, physical examination (Check-in), 12-lead ECG, and vital signs. Exclusion...
Human ADME is a Phase 1 small molecule developed by Merck & Company, Inc. (MRK). It is an absorption, metabolism, and excretion study drug evaluated in healthy adult male volunteers. The clinical program is focused on understanding how the body processes the compound rather than treating a specific disease.
Human ADME targets INSR, the insulin receptor, and acts as an agonist at that receptor. The compound is a small molecule designed to interact with INSR. This target class places it among agents that activate insulin receptor signaling.
Human ADME is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program for this compound.
Human ADME is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. The program has completed one Phase 1 trial, and no active trials are currently listed.
Human ADME has been studied in one completed Phase 1 trial, NCT01442831, titled Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects. The trial enrolled 6 healthy adult male participants in the United States and was an uncontrolled study.